Explore key U.S. health policy and insurance sector updates covering veterans' care access reforms, behavioral health workforce challenges, prescription drug pricing shifts, public health threats, and innovation in healthcare delivery.
The AMA report reveals high market concentration among pharmacy benefit managers (PBMs), vertical integration with insurers, and calls for increased transparency and regulatory reforms to control drug prices and enhance competition.
The Trump administration proceeds with the third cycle of Medicare drug price negotiations, addressing Part B drug inclusion and sparking pharmaceutical industry concerns about pricing and implementation.
North Carolina moves forward with legislative efforts to regulate pharmacy benefit managers, aiming to increase transparency and fair reimbursement for independent pharmacies amid rising drug prices.
New analysis projects increased Medicare spending with expanded GLP-1 receptor agonist coverage for obesity, highlighting clinical benefits and financial challenges.
April 2025 update on U.S. pharmaceutical regulation highlights executive orders, budget changes, CMS policies, IRA litigation, and 340B program developments shaping drug pricing and access.
